SARS-CoV-2 nucleocapsid and other non-spike viral proteins (N, M, E, NSPs)

The SARS-CoV-2 nucleocapsid (N) and other non-spike proteins, including the membrane (M), envelope (E), and 16 non-structural proteins (NSPs), are essential for the viral life cycle and pathogenesis (NIH, 2021; Frontiers, 2021). The N protein is responsible for packaging the viral RNA genome into a helical ribonucleoprotein complex and plays a key role in viral assembly and immune evasion (NIH, 2021; MDPI, 2022). Non-structural proteins like the main protease (Mpro/NSP5) and RNA-dependent RNA polymerase (RdRp/NSP12) are critical for polyprotein processing and genome replication, respectively (NIH, 2023; SciTechDaily, 2022). Unlike the highly mutable Spike protein, these non-spike proteins are relatively conserved across variants, making them ideal targets for small-molecule antivirals and T-cell-inducing vaccines (NIH, 2022; CU Anschutz, 2021). Current therapeutic strategies include inhibiting viral enzymes with drugs like Paxlovid (targeting Mpro) and Remdesivir (targeting RdRp) (NIH, 2020; SciTechDaily, 2022). Additionally, the N protein is a major diagnostic biomarker and a target for developing broad-spectrum pan-coronavirus therapies (NIH, 2023; ASM, 2023).

Other names

SARS-CoV-2 structural and non-structural proteins (excluding Spike)SARS-CoV-2 N, M, E, and NSP proteinsSARS-CoV-2 non-spike antigensSARS-CoV-2 nucleocapsid proteinSARS-CoV-2 membrane proteinSARS-CoV-2 envelope proteinSARS-CoV-2 non-structural proteins

Drugs targeting these proteins primarily function by inhibiting essential viral enzymes or disrupting structural assembly. Nirmatrelvir and ensitrelvir inhibit the main protease (Mpro/NSP5), preventing the cleavage of viral polyproteins into functional units (NIH, 2023). Remdesivir and molnupiravir target the RNA-dependent RNA polymerase (RdRp/NSP12), leading to premature termination of RNA synthesis or lethal mutagenesis (NIH, 2020). Experimental compounds like K31 target the nucleocapsid protein to block its interaction with viral RNA, thereby inhibiting genome packaging (ASM, 2023). Additionally, vaccines incorporating these proteins aim to elicit broad T-cell responses against conserved epitopes (NIH, 2022).